Company Overview - Avricore Health Inc. has appointed Rodger Seccombe as the new CEO, who previously served as the Chief Technology Officer and is the President and Co-Founder of HealthTab™ Inc. [1][2] - The company is focused on acquiring and developing early-stage technologies to advance pharmacy practice and patient care, with its flagship offering being the HealthTab™ platform [5]. HealthTab™ Platform - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, reporting data in real time and covering up to 23 key biomarkers for chronic disease management [3]. - The platform has recently expanded its testing capabilities to include bacterial and viral tests, such as strep and COVID-19 [3]. Business Model and Market Position - The HealthTab™ network model enhances the role of pharmacists in primary care, empowering patients and reducing costs and waiting times [4]. - The model offers multiple revenue streams, including equipment leasing, direct access testing, disease management programs, and integration with third-party applications [4]. Leadership Transition - Hector Bremner has resigned as CEO and director, having played a significant role in the company's growth and UK expansion [2]. - The board expresses gratitude for Bremner's contributions and looks forward to future collaborations [2].

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $203 million, reflecting a 3% increase year-over-year [25] - Prescription transaction revenue and manufacturer solutions revenue increased by 217% year-over-year [25] - Adjusted EBITDA for Q1 2025 was $69.8 million, an 11% increase year-over-year, with an adjusted EBITDA margin of 34.4% [25] Business Line Data and Key Metrics Changes - The prescription marketplace and manufacturer solutions offerings saw significant growth, with a focus on enhancing partnerships with pharmacies and pharmaceutical manufacturers [10][18] - The integrated savings program (ISP) is being evaluated for expansion into non-covered medications, indicating a strategic shift to enhance value [17] Market Data and Key Metrics Changes - Over 12 million consumers and 750,000 healthcare professionals (HCPs) utilized GoodRx in Q1 2025, demonstrating strong platform engagement [9] - The company noted ongoing uncertainty in the macroeconomic environment, including regulatory changes and consumer sentiment shifts, which could impact business [11] Company Strategy and Development Direction - The company is focused on high-impact initiatives to strengthen its position in the pharmacy ecosystem, including leadership changes and strategic partnerships [5][6] - GoodRx aims to enhance its e-commerce capabilities and integrate more deeply with pharmacy operations to improve consumer experience and pharmacy profitability [16][21] - The company is committed to investing in its brand and expanding its value proposition to consumers and HCPs [13][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the Rite Aid bankruptcy and emphasized the importance of maintaining relationships with pharmacy partners to ensure smooth transitions for consumers [11][12] - The company remains optimistic about its future growth opportunities, particularly in expanding its partnerships and enhancing its service offerings [20][22] Other Important Information - The company ended Q1 2025 with $301 million in cash and $91.7 million of unused capacity on its revolving line of credit, indicating strong liquidity [25] - A share repurchase program is in place, with approximately $189 million remaining under the $450 million authorization [25] Q&A Session Summary Question: What are the most important high-impact initiatives for the company? - Management highlighted closer partnerships with retail pharmacies and expanding brand partnerships as key initiatives to drive growth [36] Question: How has the company historically managed store closures and consumer retention? - Management indicated that they are actively working to ensure smooth transitions for consumers during pharmacy closures, emphasizing the strength of the GoodRx brand [42][45] Question: What is the impact of the shift to cost-plus pricing by larger PBMs on the company's legacy model? - Management stated that a significant portion of their business already operates on cost-plus pricing, and they remain indifferent to the reimbursement mechanism [54] Question: Is there still an opportunity with GLP medications? - Management confirmed that opportunities with GLP medications continue to exist, and they are in discussions with manufacturers to enhance consumer access [58] Question: How does the company view its exposure to Medicare beneficiaries? - Management noted that less than 30% of users are Medicare eligible, and the impact of changes in Medicare out-of-pocket costs is minimal [93][95] Question: What is the company's strategy regarding biosimilars? - Management expressed optimism about the uptake of biosimilars and their alignment with the company's affordability narrative [97]

Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform in the UK, emphasizing the role of pharmacists in chronic disease prevention and management [1][2] - The UK government is significantly investing in community pharmacies, with £645 million (approx. CAD $1.2 billion) pledged in 2024 and £617 million (approx. CAD $1.144 billion) in 2025 to enhance pharmacy-led services [5] - The company has concluded operations in Shoppers Drug Mart locations in Canada as of March 31, 2025, allowing for the redeployment of devices in Canada and the UK [3][4] Financial Performance - In 2024, total revenue increased by 37% year over year to $4,785,711, while gross profit rose by 56% to $1,880,306 [11] - The company reported a loss from operations of $668,977 in 2024, an improvement from a loss of $701,215 in 2023 [8] - Total assets decreased to $2,298,544 in 2024 from $2,538,205 in 2023, while total current liabilities dropped to $330,817 from $529,218 [8] HealthTab™ Expansion - The HealthTab™ platform launched in North East London in November 2024, targeting areas with high cardiovascular disease burdens [13] - The initiative is supported by local health authorities and aims to integrate with NHS digital systems to modernize care pathways [13][14] - The platform has already conducted over 930,000 blood pressure screenings in 6,000 pharmacies, demonstrating strong uptake [14][6] Future Strategy - The company plans to expand HealthTab™ into other major population centers in the UK, focusing on diverse demographics suitable for preventative health programs [15] - Following initial successes, the company aims to work with NHS stakeholders for broader adoption of HealthTab™, potentially integrating cholesterol testing into the Pharmacy First protocol [16] - Momentum is expected to grow throughout 2025 as NHS plans for expanding point-of-care testing in community pharmacies become clearer [17] Market Context - The point-of-care testing market is projected to reach $93.21 billion USD by 2030, indicating significant growth potential for HealthTab™ [19] - The UK government’s investment in pharmacy-led services aligns with the increasing demand for accessible healthcare solutions amid rising chronic disease rates [5][6]

Key Takeaways We're nearing the end of the calendar-year Q1, with many S&P 500 stocks delivering strong performances year- to-date despite recent volatility stemming from tariff talks and other economic developments. And concerning the all-star performers, Philip Morris (PM) , CVS Health (CVS) , and Newmont (NEM) all reflect top-performing S&P 500 stocks. Let's take a closer look at what's been driving the positivity. PM Pays Shareholders Handsomely Philip Morris shares have benefited nicely from its latest ...